AAN Conference Perspectives - Episode 1
Aaron Miller, MD, Hideki Garren, MD, and Kate Dawson, MD, discuss the top findings for teriflunomide, ocrelizumab, and tecfidera plus tysabri from the The 69th American Academy of Neurology Annual Meeting for patients with multiple sclerosis.
Miller, professor of Neurology and medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Hospital in New York, discusses the safety profile of teriflunomide for patients with multiple sclerosis.
Garren, group medical director, Genentech & Roche Pharmaceutical, discusses ocrelizumab (Ocrevus) for relapsing, primary progressive multiple sclerosis.
Dawson, VP, US Medical Biogen, discusses early treatment with tecfidera and tysabri for patients with multiple sclerosis.